Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000760627 | SCV000890519 | likely pathogenic | not provided | 2018-07-24 | criteria provided, single submitter | clinical testing | The R59X variant in the IMPG1 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R59X variant is observed in 7/246,038 (0.0028%) global alleles in large population cohorts and no individuals were reported to be homozygous (Lek et al., 2016). We interpret R59X as a likely pathogenic variant. |
Labcorp Genetics |
RCV000760627 | SCV001411525 | pathogenic | not provided | 2024-10-11 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg59*) in the IMPG1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in IMPG1 are known to be pathogenic (PMID: 23993198). This variant is present in population databases (rs200651043, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with IMPG1-related conditions. ClinVar contains an entry for this variant (Variation ID: 620263). For these reasons, this variant has been classified as Pathogenic. |